Application of cilostazol for preparing medicine to treat bradycardia

Abstract

An application of cilostazol in preparing the medicine for treating bradycardia is disclosed.

Description

technical field [0001] The invention relates to a new application of cilostazol in pharmacy, in particular to an application of cilostazol in preparing a medicine for treating bradycardia. Background technique [0002] Cilostazol is a small molecular weight compound, which was developed by Otsuka Pharmaceutical Co., Ltd. in Japan as a new drug for the treatment of chronic arterial occlusive disease. It was launched in Japan in 1988 and was approved by the US FDA in May 1999 for the treatment of stable intermittent limp. This product has been imported in my country, the trade name is "Peda", the registration certificate number is X20000342, and it is suitable for improving ischemic symptoms such as ulcers, limb pain, cold sensation and intermittent claudication caused by chronic arterial occlusive disease. [0003] The main features of cilostazol tablets as a drug for the treatment of chronic arterial occlusive disease are as follows: [0004] 【Drug Name】 [0005] Generic ...

AI Technical Summary

Problems solved by technology

[0019] (2), toxicity

[0022] 3. Carcinogenicity, mutagenicity and reproductive toxicity Rats and mice were given cilostazol 500mg / kg / day and 1000mg / kg / day in the diet respectively for 104 weeks, no carcinogenicity was found

However, the chromosomal mutation rate of Chinese hamster ovary cells in vitro was significantly increased

[0023] 4. Antigenicity No antigenicity

[0024] (3) General Pharmacology In addition to the circulatory system effects such as relaxing vascular smooth muscle, increasing heart rate, and enhancing myocardial contractility, there are almost no other effects

Images